Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FSC
|
|||
| Former ID |
DNC014272
|
|||
| Drug Name |
NP-118809
|
|||
| Synonyms |
41332-24-5; NP118809; Z-160; 1-[4-(Diphenylmethyl)-1-piperazinyl]-3,3-diphenyl-1-propanone; UNII-TX3R141LEP; TX3R141LEP; CHEMBL604710; Piperazine, 1-(diphenylmethyl)-4-(1-oxo-3,3-diphenylpropyl)-; 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one; AC1NLRM8; GTPL7765; SCHEMBL4180792; CTK1D3910; DTXSID70407284; VCPMZDWBEWTGNW-UHFFFAOYSA-N; MolPort-001-545-055; EX-A2422; BCP08259; KS-00000T6R; ZINC20509316; 3934AH; STK411255; AKOS003297641; MK-6721; DB12743; MCULE-3294187169; CS-1361; API0014038; ACM41332245
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Discontinued in Phase 2 | [1] | |
| Therapeutic Class |
Analgesics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H32N2O
|
|||
| Canonical SMILES |
C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5
|
|||
| InChI |
1S/C32H32N2O/c35-31(25-30(26-13-5-1-6-14-26)27-15-7-2-8-16-27)33-21-23-34(24-22-33)32(28-17-9-3-10-18-28)29-19-11-4-12-20-29/h1-20,30,32H,21-25H2
|
|||
| InChIKey |
VCPMZDWBEWTGNW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 41332-24-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7359768, 8527374, 16528523, 46428343, 58047930, 61737298, 79084327, 88388044, 99431576, 103729219, 104145806, 104271154, 107844845, 118765067, 134351477, 142845073, 143784140, 162526807, 163620796, 163686121, 164840806, 169998639, 186014788, 223366098, 230132986, 242059872, 244736914, 252421380, 252480256
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | MAPK signaling pathway | |||
| Cardiac muscle contraction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Oxytocin signaling pathway | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| Dilated cardiomyopathy | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||
| WikiPathways | Arrhythmogenic Right Ventricular Cardiomyopathy | |||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016715) | |||
| REF 2 | Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.